A Case of Pneumocystis Pneumonia after Cetuximab-based Bioradiotherapy

Asano Shinohara, Ryunosuke Kogo, Hideoki Uryu, Ryuji Yasumatsu, Torahiko Nakashima, Shizuo Komune

Research output: Contribution to journalArticle


Reports of drug-induced interstitial pneumonia caused by Cetuximab have been increasing. Pneumocystis pneumonia is important as a differential diagnosis of drug-induced interstitial pneumonia. We report herein on a 64-year-old man with pneumocystis pneumonia after cetuximab-based bioradiotherapy for laryngeal cancer. After radiotherapy, the patient developed multi-drug resistant pneumonia. Chest CT imaging revealed diffuse ground-glass opacities in the lung field. He was diagnosed as having pneumocystis pneumonia based on the bronchoalveolar lavage (BAL) findings, and then his symptoms improved after treatment with Trimethoprim/Sulfamethoxazole. It is important to assess the risk factor for pneumocystis pneumonia for early its detection and treatment.

Original languageEnglish
Pages (from-to)204-209
Number of pages6
JournalNihon Jibiinkoka Gakkai kaiho
Issue number3
Publication statusPublished - Mar 1 2016


All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology

Cite this

Shinohara, A., Kogo, R., Uryu, H., Yasumatsu, R., Nakashima, T., & Komune, S. (2016). A Case of Pneumocystis Pneumonia after Cetuximab-based Bioradiotherapy. Nihon Jibiinkoka Gakkai kaiho, 119(3), 204-209.